The latest price target for Marinus Pharma (NASDAQ:MRNS) was reported by Cantor Fitzgerald on November 14, 2024. The analyst firm set a price target for $4.00 expecting MRNS to rise to within 12 months (a possible 1555.63% upside). 33 analyst firms have reported ratings in the last year.

The latest analyst rating for Marinus Pharma (NASDAQ:MRNS) was provided by Cantor Fitzgerald, and Marinus Pharma reiterated their overweight rating.

The last upgrade for Marinus Pharmaceuticals Inc happened on September 23, 2024 when Oppenheimer raised their price target to $6. Oppenheimer previously had a perform for Marinus Pharmaceuticals Inc.

The last downgrade for Marinus Pharmaceuticals Inc happened on October 25, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Marinus Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Marinus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Marinus Pharma was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Marinus Pharma (MRNS) rating was a reiterated with a price target of $4.00 to $4.00. The current price Marinus Pharma (MRNS) is trading at is $0.24, which is out of the analyst’s predicted range.